Italy· 049375013

GADUAR

A olmesartan medoxomil, amlodipin und hydrochlorothiazid product containing olmesartan medoximil + amlodipina + idroclorotiazide, registered in Italy by ZENTIVA ITALIA S.R.L., on the national reimbursement list. The same ATC class is registered in 9 of our 19 countries.

Reimbursed in Italy (AIFA class A)ATC C09DX03

Checked against AIFA (Italy) on

Informational only — not a medical device.

SOURCE REGISTER · ITAIFA (Italy)normalisedGADUARATCC09DX03REGISTER NO.049375013PACKS LISTED1CHECKEDSeptember 28, 2026

Where it is registered

Olmesartan medoxomil, amlodipin und hydrochlorothiazid is registered in 9 of 19 countries.

Countries holding a registration under ATC C09DX03 (olmesartan medoxomil, amlodipin und hydrochlorothiazid), each read from that country’s own register.

  • This record: Italy, from AIFA (Italy)
  • 7 of them publish a price we can compare per daily dose

Olmesartan medoxomil, amlodipin und hydrochlorothiazid · ATC C09DX03

9 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Finlandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Polandprice
  • Spainprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

AIFA (Italy)
Active substance
Olmesartan medoximil + Amlodipina + Idroclorotiazide
Manufacturer
ZENTIVA ITALIA S.R.L.
Country
Italy (IT)
ATC code
C09DX03
ATC class
Olmesartan medoxomil, Amlodipin und Hydrochlorothiazid
Reimbursed
Yes
Source register
AIFA (Italy)
Last checked
September 28, 2026

Packs & prices · 1

1 priced
  • aic
    049375013
    "20 MG/5 MG/12,5 MG COMPRESSE RIVESTITE CON FILM" 28 COMPRESSE IN BLISTER AL/AL
    EUR 8.72

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

36 interactions on record for olmesartan medoxomil, amlodipin und hydrochlorothiazid.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Olmesartan medoxomil, amlodipin und hydrochlorothiazid · interactions on record

36 records

36 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
Mechanism and what to do, in the interaction check
Interaction register. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of AIFA (Italy). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/d01a9df6-00a5-43de-8e48-96dc7c8f1fb0
GET /v1/drugs/d01a9df6-00a5-43de-8e48-96dc7c8f1fb0?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "pack": "\"20 MG/5 MG/12,5 MG COMPRESSE RIVESTITE CON FILM\" 28 COMPRESSE IN BLISTER AL/AL",
  "source": "aifa",
  "currency": "EUR",
  "substance": "Olmesartan medoximil + Amlodipina + Idroclorotiazide",
  "reference_pack": "28 UNITA' (20+5+12,5) MG - USO ORALE",
  "public_price_eur": 8.72,
  "ssn_reference_price_eur": 8.72
}

See everything about olmesartan medoxomil, amlodipin und hydrochlorothiazid.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.